GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
This retrospective cohort study used the TriNetX Research Network — a large federated database — to examine whether GLP-1 receptor agonists (GLPs: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, albiglutide, and lixisenatide) were associated with reduced postoperative inflammatory complications (IC) in patients undergoing dermatologic surgery. The study population included patients who underwent Mohs Micrographic Surgery or wide local excisions for melanoma or nonmelanoma skin cancer. Outcomes tracked over one month included wound disruption, hematoma, post-procedure infection, skin and subcutaneous tissue infection, and other procedural complications. After adjusting for demographics and proinflammatory comorbidities using hazard ratios and 95% confidence intervals, the study found that GLP use was associated with a statistically significant reduction in all measured IC categories compared with non-GLP users. Semaglutide and tirzepatide showed the largest individual reductions. Limitations include the retrospective, observational design — which cannot establish causation — along with potential residual confounding, database coding inaccuracies, and inability to control for medication adherence or surgical technique variability.
Why this grade: While the study uses human real-world data, its retrospective observational design using a claims/EHR database precludes causal inference and is subject to residual confounding, limiting the strength of evidence.
Background Glucagon-like peptide-1 (GLP) receptor agonists have demonstrated anti-inflammatory and wound-healing properties, but their impact on outcomes after dermatologic surgery has not been evaluated. Objective This study assessed the one-month risk of postoperative inflammatory complications (IC) in patients taking GLPs. Methods Patients undergoing Mohs Micrographic Surgery and wide local excisions for melanoma or nonmelanoma skin cancer while taking a GLP were identified using the TriNetx Research Network. GLPs included semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, albiglutide, and lixisenatide. IC included wound disruption, hematoma, infection of the skin and subcutaneous tissue, infections after a procedure, and other complications of procedures. After accounting for demographics and proinflammatory comorbid conditions, hazard ratios and 95% confidence intervals were used to identify the one-month risk of postoperative complications. Results Compared with patients without GLP use, the GLP cohort was associated with a significantly reduced risk of infection after a procedure, wound disruption, skin and subcutaneous tissue infection, hematoma, and other complications. Among individual drug comparisons, semaglutide and tirzepatide demonstrated the greatest reductions in postoperative complications. Conclusion GLP receptor agonists were associated with a significantly reduced risk of postoperative inflammatory complications after dermatologic surgery, supporting their perioperative safety and potential beneficial role in wound healing.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.